Cardiogen Research Guide: Cardiac Bioregulator Peptide

By NorthPeptide Research Team · April 5, 2026

What Is Cardiogen?

Cardiogen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Arg (alanine-glutamic acid-aspartic acid-arginine). It belongs to the class of “bioregulator” or “cytomax” peptides developed over several decades by Professor Vladimir Khavinson, an immunologist and gerontologist at the St. Petersburg Institute of Bioregulation and Gerontology (IBG) in Russia.

The Khavinson bioregulator peptide program, which has been ongoing since the 1970s, is based on a foundational hypothesis: that organ- and tissue-specific short peptides extracted from animal tissues can serve as endogenous regulatory signals that maintain the gene expression programs characteristic of healthy, youthful cellular function. Under this framework, each tissue produces its own regulatory peptide complement, and aging or pathological conditions are associated with the depletion of these tissue-specific signals.

Cardiogen was specifically derived from cardiac tissue — it was originally identified through bioregulator extraction from bovine heart muscle and subsequently characterized and synthesized. The sequence Ala-Glu-Asp-Arg was determined to be the minimal bioactive unit responsible for the cardiac-specific regulatory effects of the native extract.

Other notable members of the Khavinson bioregulator family include:

• Epithalon (Ala-Glu-Asp-Gly) — pineal gland bioregulator, primarily researched for telomere maintenance and circadian rhythm regulation
• Cortagen (Ala-Glu-Asp-Pro) — cerebral cortex bioregulator, researched for neuroprotective effects
• Crystagen (Ala-Glu-Asp-Leu) — thymus bioregulator, researched for immune modulation
• Vesugen (Lys-Glu-Asp) — vascular bioregulator, researched for endothelial function
• Pinealon (Glu-Asp-Arg) — brain bioregulator for CNS function

The striking structural similarity of these peptides — most share the Ala-Glu-Asp core with differing fourth residues — has led to the hypothesis that the tissue specificity is determined by this fourth amino acid, which encodes tissue-targeting information, while the Ala-Glu-Asp core provides the fundamental regulatory activity.

Mechanism of Action

The proposed mechanism of Cardiogen and the Khavinson bioregulator class centers on direct interaction with DNA regulatory elements in the cell nucleus — a mechanism that distinguishes this peptide class from receptor-ligand signaling models used by most research peptides.

Chromatin and Gene Regulation

The core mechanistic hypothesis for the Khavinson bioregulators, supported by research from IBG and collaborating institutions, is that these short peptides interact with histone proteins and chromatin — the protein-DNA complexes that package chromosomal DNA and regulate gene accessibility. Specifically:

• Histone binding — Short peptides of 2–5 amino acids have been shown in biophysical studies to interact with histone H1, a linker histone that plays a role in chromatin compaction and gene silencing. Binding of bioregulator peptides to histone H1 has been proposed to relax chromatin compaction locally, increasing the accessibility of DNA to transcription factors.
• DNA binding — Some studies using molecular modeling and fluorescence spectroscopy have suggested that Khavinson peptides can interact directly with specific DNA sequences — particularly CGCG and TATA box motifs — potentially acting as gene expression modulators by influencing transcription factor binding site accessibility.
• Gene expression activation — The net result of these chromatin interactions is proposed to be activation of tissue-specific gene expression programs. For Cardiogen, this means activation of genes relevant to cardiomyocyte function, repair, and survival — genes that may be silenced during aging or pathological stress through chromatin remodeling.

This “epigenetic regulator” hypothesis — that Cardiogen works by modulating chromatin structure and gene accessibility rather than by binding to a cell surface receptor — is the primary distinguishing feature of the Khavinson bioregulator class. It is consistent with the observation that these peptides appear to produce tissue-specific effects despite their short, structurally simple sequences.

Cardiac Tissue Specificity

A central claim of the bioregulator model is tissue specificity — that Cardiogen’s effects are preferentially expressed in cardiac tissue rather than being broadly distributed. The proposed basis for this specificity includes:

• Affinity for the chromatin structure characteristic of cardiomyocytes, shaped by the epigenetic modifications specific to cardiac tissue identity
• Preferential uptake or retention by cardiac cells
• Activation of gene expression programs that are pre-configured in cardiomyocytes but not in other cell types

Research published by Khavinson and colleagues has tested tissue specificity using radioactively labeled peptide analogs and autoradiography, reporting preferential distribution to target tissues following administration. However, it should be noted that the degree of tissue specificity observed in these studies has not been universally replicated with modern pharmacokinetic techniques, and the mechanistic basis for selectivity remains an active area of investigation.

Antioxidant Activity

Independent of the chromatin-interaction mechanism, some studies have documented direct antioxidant properties of Cardiogen and related bioregulators. Short peptides containing acidic amino acids (Glu, Asp) have been shown to scavenge reactive oxygen species (ROS) and chelate transition metal ions that catalyze oxidative reactions. In the context of cardiac research, where oxidative stress is a primary driver of ischemia-reperfusion injury, this antioxidant activity is mechanistically relevant and complementary to the gene regulatory mechanism.

Cardioprotection Research

Ischemia-Reperfusion Models

The most extensively studied application of Cardiogen in preclinical research is cardioprotection in ischemia-reperfusion (I/R) injury models. Cardiac I/R injury occurs when a coronary artery occlusion (ischemia) is followed by restoration of blood flow (reperfusion) — a process that paradoxically causes additional cardiac damage through oxidative burst, calcium overload, and mitochondrial permeability transition.

Studies using rodent I/R models have investigated the effect of Cardiogen pretreatment or post-ischemic treatment on:

• Infarct size — Multiple studies have reported reductions in myocardial infarct area (as a percentage of area at risk) in Cardiogen-treated animals compared to controls. The magnitude of reported protection ranges from 20–40% reduction in infarct size.
• Cardiomyocyte apoptosis — TUNEL staining and caspase activation assays have shown reduced cardiomyocyte apoptosis in Cardiogen-treated I/R hearts, consistent with an anti-apoptotic mechanism protecting cells from ischemia-induced programmed death.
• Contractile function recovery — Echocardiographic measurements in I/R models have documented improved left ventricular function (ejection fraction, fractional shortening) in Cardiogen-treated animals following reperfusion, consistent with reduced myocardial stunning and improved cardiomyocyte viability.
• Oxidative stress markers — Reduced malondialdehyde (MDA, a lipid peroxidation marker) and enhanced superoxide dismutase (SOD) activity in cardiac tissue of Cardiogen-treated animals suggest antioxidant protection contributing to cardioprotection.

Aging Cardiac Models

Professor Khavinson’s group has placed particular emphasis on the relevance of bioregulators to age-related cardiac decline. The aging heart is characterized by progressive changes in cardiomyocyte gene expression, mitochondrial dysfunction, increased oxidative stress, and reduced regenerative capacity. Research with Cardiogen in aged animal models has examined:

• Restoration of cardiac gene expression programs toward a more youthful profile in aged rodent hearts
• Improvements in mitochondrial function parameters in aged cardiomyocytes exposed to Cardiogen
• Reduction in age-related cardiac fibrosis markers
• Improved functional parameters (heart rate variability, contractility indices) in aged animals following Cardiogen treatment

A study published in the Bulletin of Experimental Biology and Medicine (Khavinson et al., 2004) documented Cardiogen-induced changes in gene expression and histological parameters consistent with cardioprotective activity in animal models.

Cardiomyocyte Culture Studies

In vitro studies using isolated cardiomyocyte cultures have provided mechanistic insight into Cardiogen’s cellular effects. Key findings include:

• Reduced susceptibility of cardiomyocytes to hypoxia-induced apoptosis in Cardiogen-treated cultures compared to controls
• Enhanced expression of heat shock proteins (HSP70, HSP90) — intracellular chaperones that protect cells from stress-induced protein damage
• Modulation of NF-κB signaling, a central transcriptional regulator of the inflammatory and survival response in cardiomyocytes
• Increased expression of Bcl-2 family anti-apoptotic proteins relative to pro-apoptotic Bax, shifting the apoptotic balance toward cell survival

Comparison to Other Cardiac-Relevant Peptides

Cardiogen occupies a distinct mechanistic niche among cardiac research peptides. Unlike BPC-157, which operates through angiogenesis and VEGF upregulation, or SS-31, which directly protects the mitochondrial inner membrane, Cardiogen’s proposed gene regulatory mechanism targets the transcriptional level — modulating which genes are expressed rather than directly modulating the activity of individual proteins. This upstream mechanism may provide durable effects that persist after the peptide is eliminated, if epigenetic modifications are maintained.

Dosing in Research Models

Cardiogen, like other Khavinson bioregulators, is typically used at very low doses (microgram range) compared to many research peptides. This is consistent with the proposed gene regulatory mechanism, where the peptide functions as a signaling molecule rather than a substrate, and where small quantities are sufficient to activate downstream transcriptional programs.

Reconstitution and Handling

• Storage — Lyophilized Cardiogen at -20°C. Stable for 24+ months when properly stored; protect from moisture and repeated temperature fluctuations.
• Reconstitution — Reconstitute with sterile bacteriostatic water or sterile saline. Cardiogen is a tetrapeptide and dissolves readily in aqueous solution.
• Concentration — Typical research concentrations: 100–500 μg/mL for subcutaneous injection use, allowing accurate delivery of the low doses characteristic of this compound class.
• Stability post-reconstitution — Refrigerate at 2–8°C; use within 30 days of reconstitution. Bacteriostatic water extends stability by preventing microbial contamination.
• Dose accuracy — At the low doses used in research, accurate measurement is important. Use calibrated insulin syringes or micropipettes appropriate for the volumes required.

Safety Profile

Cardiogen belongs to the Khavinson bioregulator class, which has been studied for approximately five decades. Key safety observations:

• No acute toxicity — Acute toxicity studies in rodents at doses substantially above research ranges have not produced adverse findings. The tetrapeptide’s metabolic fate is degradation to four amino acids (alanine, glutamic acid, aspartic acid, arginine) — all natural, non-toxic compounds.
• No organ toxicity — Liver, kidney, and hematological parameters have been normal in subchronic exposure studies with Khavinson bioregulator class peptides.
• No hormonal disruption — Unlike peptides that engage endocrine receptors, Cardiogen’s proposed gene regulatory mechanism does not involve direct hormonal axis activation.
• Tissue specificity as a safety feature — If the cardiac tissue-specificity of Cardiogen’s effects is robust, off-target effects in non-cardiac tissues would be minimized.
• Long clinical experience in Russia — Khavinson bioregulators including Cardiogen have been used clinically in Russia, where they are available as dietary supplements (under the Cytomax brand), providing a long-term observational safety record.

Current Limitations and Future Directions

• Independent replication needed — The majority of Cardiogen research originates from Khavinson’s own group at IBG St. Petersburg. Independent replication of key findings by unaffiliated laboratories is needed for broader scientific acceptance.
• Mechanism requires deeper characterization — The chromatin/histone interaction mechanism, while supported by biophysical studies, requires validation using modern genomics tools (ChIP-seq, ATAC-seq) in cardiac cell systems.
• No Western clinical trials — Cardiogen has not been evaluated in double-blind, placebo-controlled randomized trials meeting modern Western clinical trial standards.
• Pharmacokinetics not fully characterized — Tissue distribution, half-life, and clearance of Cardiogen have not been fully characterized using modern pharmacokinetic methods.
• Dose-response relationships — Systematic dose-response studies are limited; optimal dosing for specific research applications requires additional characterization.

Future research priorities include independent mechanistic validation using modern epigenomics tools, rigorous dose-response characterization, Western-standard preclinical studies using validated cardiac injury models, and ultimately human clinical trials in cardiac indications where the mechanism predicts benefit.

Summary of Key Research References

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.